Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384 - PubMed (original) (raw)
Randomized Controlled Trial
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384
Rajesh T Gandhi et al. J Acquir Immune Defic Syndr. 2006.
Abstract
Objective: To assess the effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy (ART).
Methods: Nine hundred eighty antiretroviral-naive HIV-1+ subjects were randomized to start stavudine/didanosine or zidovudine/lamivudine with nelfinavir, efavirenz, or both nelfinavir and efavirenz.
Results: Greater CD4 cell recovery was associated with age of 40 years or younger, female sex, higher baseline naive/memory CD4 cell ratio, higher baseline virus load (VL), and virologic suppression (VS). Most subjects who maintained an undetectable VL had a substantial increase in CD4 cell count, but 13% of the subjects did not, even after 3 years of VS. Persistent T-cell activation was associated with lower CD4 cell recovery, even in subjects who achieved VS. Initial treatment assignment did not affect total CD4 cell recovery, naive/memory CD4 cell reconstitution, or decline in T-cell activation. In addition to CD4 cell recovery, B-cell counts rose substantially after ART initiation.
Conclusions: In this large randomized trial, younger age, female sex, higher naive/memory CD4 cell ratio, higher baseline VL, and VS were associated with greater CD4 cell increase, whereas persistent T-cell activation was associated with impaired CD4 cell recovery after ART initiation. Initial treatment assignment did not affect CD4 cell reconstitution.
Similar articles
- Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.
Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. Evans TG, et al. Antiviral Res. 1998 Oct;39(3):163-73. doi: 10.1016/s0166-3542(98)00035-7. Antiviral Res. 1998. PMID: 9833957 Clinical Trial. - Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Verweel G, et al. Pediatrics. 2002 Feb;109(2):E25. doi: 10.1542/peds.109.2.e25. Pediatrics. 2002. PMID: 11826235 - Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
Cuong DD, Sönnerborg A, Van Tam V, El-Khatib Z, Santacatterina M, Marrone G, Chuc NT, Diwan V, Thorson A, Le NK, An PN, Larsson M. Cuong DD, et al. BMC Infect Dis. 2016 Dec 16;16(1):759. doi: 10.1186/s12879-016-2017-x. BMC Infect Dis. 2016. PMID: 27986077 Free PMC article. Clinical Trial. - Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MM; ACTG 315 Team. Wu H, et al. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1231-40. doi: 10.1089/088922201750461285. AIDS Res Hum Retroviruses. 2001. PMID: 11559422 Clinical Trial. - Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL, Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, Gonzalez CJ, Schnizlein-Bick CT, Evans T, Squires KE, Phair JP. Landay AL, et al. AIDS Res Hum Retroviruses. 2002 Jan 20;18(2):95-102. doi: 10.1089/08892220252779638. AIDS Res Hum Retroviruses. 2002. PMID: 11839142 Clinical Trial.
Cited by
- Machine learning models based on fluid immunoproteins that predict non-AIDS adverse events in people with HIV.
Premeaux TA, Bowler S, Friday CM, Moser CB, Hoenigl M, Lederman MM, Landay AL, Gianella S, Ndhlovu LC. Premeaux TA, et al. iScience. 2024 May 8;27(6):109945. doi: 10.1016/j.isci.2024.109945. eCollection 2024 Jun 21. iScience. 2024. PMID: 38812553 Free PMC article. - Impacts of plasma microbial lipopolysaccharide translocation on B cell perturbations and anti-CD4 autoantibody production in people with HIV on suppressive antiretroviral therapy.
Fu X, Cheng D, Luo Z, Heath SL, Adekunle R, McKinnon JE, Martin L, Sheng Z, Espinosa E, Jiang W. Fu X, et al. Cell Biosci. 2023 May 3;13(1):78. doi: 10.1186/s13578-023-01022-6. Cell Biosci. 2023. PMID: 37138358 Free PMC article. - Naïve B cells with low differentiation improve the immune reconstitution of HIV-infected patients.
Jia J, Zhao Y, Yang JQ, Lu DF, Zhang XL, Mao JH, Wang KH, Wang JH, Kuang YQ. Jia J, et al. iScience. 2022 Nov 13;25(12):105559. doi: 10.1016/j.isci.2022.105559. eCollection 2022 Dec 22. iScience. 2022. PMID: 36465118 Free PMC article. - CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults.
Fiseha T, Ebrahim H, Ebrahim E, Gebreweld A. Fiseha T, et al. PLoS One. 2022 Mar 24;17(3):e0265740. doi: 10.1371/journal.pone.0265740. eCollection 2022. PLoS One. 2022. PMID: 35324948 Free PMC article. - The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study.
Chen J, Titanji K, Sheth AN, Gandhi R, McMahon D, Ofotokun I, Weitzmann MN, De Paris K, Dumond JB. Chen J, et al. Immun Ageing. 2022 Jan 3;19(1):4. doi: 10.1186/s12979-021-00260-x. Immun Ageing. 2022. PMID: 34980186 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- AI25879/AI/NIAID NIH HHS/United States
- AI27659/AI/NIAID NIH HHS/United States
- AI27666/AI/NIAID NIH HHS/United States
- AI38855/AI/NIAID NIH HHS/United States
- AI38858/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials